Recent advances: HIV infection - II

British Medical Journal

Volumn 314, Issue 7080, 1997, Pages 579-583

  Beiser, Claire ^a  

^a INSTITUTE OF HUMAN VIROLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; RETINITIS; SHORT SURVEY; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 0031039971     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.314.7080.579     Document Type: Short Survey

References (56)

1. Lucas SS, Hounnou A, Peacock C, Beaumel A, Djomand G, N'Gbichi J-M, et al. The mortality and pathology of HIV infection in a West African city. AIDS 1993;7:1569-79.
2. Supparatpinyo K, Khamwan, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in Southeast Asia. Lancet 1994;344:110-3.
3. Montalban C, Martinez-Fernandez R, Calleja JL de D, Garcia-Diaz J, Rubio R, Dronda F, et al. Visceral leishmaniasis (kala-azar) as an opportunistic infection in patients infected with the human immunodeficiency virus in Spain. Rev Infect Dis 1989;11:655-60.
4. Enger C, Graham N, Peng Y, Chmiel JS, Kingsley LA, Detels R, et al. Survival from early, intermediate, and late stages of HIV infection. JAMA 1996;275:1329-34.
5. Jones JL, Hanson DL, Ward JW, Kaplan JE. Incidence trends in AIDS-related opportunistic illnesses in injecting drug users and men who have sex with men. XI International Conference on AIDS, Vancouver, 1996. (Abstract WeC2418.)
6. Dore G, Kaldor J, Hoy J, Mallal S, Li Y, Mijch M, et al. Trends in AIDS-related illness in Australia: the Australian AIDS Cohort. XI International Conference on AIDS, Vancouver, 1996. (Abstract TuB2236.)
7. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996;124:633-42.
8. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clin Infect Dis 1995;21(suppl 1):S32-43.
9. Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992;165:1082-5.
10. Nightingale SD, Cameron WD, Gordin FM, Sullani PM, Cohn DL, Chaisson RE, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993;329:828-33.
11. Oldfield EC, Dickinson G, Chung R, Wallace MR, Craig DB, Fessel WJ, et al. Once weekly azithromycin for the prevention of Mycobacterium avium complex (MAC) infection in AIDS patients. Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996. (Abstract 203.)
12. Pierce M, Crampton S, Henry D, Heifets L, LaMarca A, Montecalva M, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996;335:384-91.
13. Havlir DV, Dubé MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996;335:392-8.
14. 3. XI International Conference on AIDS, Vancouver, 1996. (Abstract WeB421.)
15. Moore RD, Chaisson RE. Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS. AIDS 1995;9:1337-42.
16. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23:685-93.
17. Shafran SD, Singer J, Zarowny DP, Phillips P, Salit I, Walmsley S, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol and clarithromycin versus rifampin, ethambutol, clofazimine and ciprofloxacin. N Engl J Med 1996;335:377-83.
18. May T, Vincent V, Brel F, Beuscart CI, Perronne C, Doco-Lecompte T, et al. The French randomized clinical trial of combination therapy with clarithromycin for MAC bacteremia in AIDS patients: final results. XI International Conference on AIDS, Vancouver, 1996. (Abstract WeB422.)
19. Dubé M, Sattler F, Torriani F, See D, Havlir D, Kemper C, et al. Prevention of relapse of MAC bacteremia in AIDS: a randomized study of clarithromycin plus clofazimine, with or without ethambutol. Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996. (Abstract 206.)
20. Chaisson RE, Keiser P, Pierce M, Fessel WJ, Ruskin J, Lahart C, Meek K. Controlled trial of clarithromycin/ethambutol with or without clofazimine for Mycobacterium avium complex bacteremia in AIDS. Third Conference on Retro viruses and Opportunistic Infections, Washington, DC, 1996.
21. Hoover DR, Saah AJ, Bacellar H, Phair J, Detels R, Anderson R, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med 1993;329:1922-6.
22. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. N Engl J Med 1992;326:213-20.
23. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. The Oral Ganciclovir European and Australian Cooperative Study Group. AIDS 1995;9:471-7.
24. Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA, et al. For the Syntex Cooperative Oral Ganciclovir Study Group. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995;333:615-20.
25. Squires KE, Stempien MJ, Shadman A, Buliles WC. Oral ganciclovir versus intravenous ganciclovir maintenance therapy for cytomegalovirus retinitis in patients with AIDS: preliminary results of a phase III study. First National Conference on Human Retroviruses and Related Infections, Washington, DC, 1993. (Abstract 540.)
26. Lalezari J, Friedberg D, Bisset J, Giordano M, Hardy D, Robinson C. A comparison of the safety and efficacy of 3 g, 4.5 g, and 6 g doses of oral ganciclovir versus IV ganciclovir for maintenance treatment of CMV retinitis. XI International Conference on AIDS, Vancouver, 1996. (Abstract ThB305.)
27. Kupperman B, Lalezari J, Stagg R, Kramer F, Holland G, Ives D, et al. A phase II/III randomized study of immediate versus deferred intravenous cidofovir for AIDS patients with peripheral CMV retinitis. International Symposium on Experimental and Clinical Ocular Pharmacology and Pharmaceutics, Geneva, 1995.
28. Sanborn GE, Anand R, Torti RE, Nightingale SD, Cal SX, Yates B, et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. Arch Ophthalmol 1992;110:188-95.
29. Martin DF, Parks DJ, Mellow SO, Ferris FL, Walton RC, Remaley NA, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Opthalmol 1994;112:1531-9.
30. Chiron ganciclovir implant study group. A randomized controlled multicenter clinical trial of a sustained-release intraocular ganciclovir implant in AIDS patients with CMV retinitis. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995. (Abstract 1215).
31. Rahhal FM, Arevalo JF, Chavez de la Paz E, Munguia D, Azen SP, Freeman WR. Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. Ann Intern Med 1996;125:98-103.
32. Lalezari JP, Kemper C, Stagg R, Holland G, Ives D, Kramer F, et al. A randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. XI International Conference on AIDS, Vancouver, 1996. (Abstract ThB304.)
33. Studies of Ocular Complication of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. Arch Ophthalmol 1996;114:23-33.
34. Spector SA, McKinley GF, Lalezari JP, Samo T, Acdruczk R, Follansbee S, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996;334:1491-7.
35. Brosgart C, Craig C, Hillman D, Louis TA, Alston B, Fisher E, et al. Final results from a randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of CMV retinal and gastrointestinal mucosal disease. XI International Conference on AIDS, Vancouver, 1996. (Abstract ThB301.)
36. Advances in the management of AIDS-related cytomegalovirus retinitis. NIH Conference; H Masur, moderator. Ann Intern Med 1996;125:126-36.
37. Perriëns JH, St. Louis ME, Mukadi YB, Brawn C, Prignot J, Pouthier F, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995;332:779-84.
38. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GN, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328:521-6.
39. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City - turning the tide. N Engl J Med 1995;333:229-33.
40. Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney B, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330:1179-84.
41. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh R. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-32.
42. Turett GS, Telzak EE, Torian LV, Blum S, Alland D, Weisfuse I, et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995;21:1238-44.
43. Salomon N, Perlman DC, Friedmann P, Buchstein S, Kreiswirth B, Mildvan D. Predictors and outcome of multidrug-resistant tuberculosis. Clin Infect Dis 1995;21:1245-52.
44. Barnes PF, El-Haji H, Preston-Martin S, Cave MD, Jones BE, Otaya M, et al. Transmission of tuberculosis among the urban homeless. JAMA 1996;275:305-7.
45. Alland D, Kalkut GE, Moss AR, McAdam RA, Hahn JA, Bosworth W, et al. Transmission of tuberculosis in New York city. An analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994;330:1710-6.
46. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. N Engl J Med 1995;332:1181-5.
47. Chang Y, Cesarman E, Pessin MS, Le F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9.
48. Chang Y, Ziegler J, Wabinga H, Katangole-Mbidde E, Boshoff C, Schulz T, et al. Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa. Arch Intern Med 1996;156:202-4.
49. Whithy D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995;346:799-802.
50. Monini P, de Lellis L, Fabris M, Rigolin F, Cassai E. Kaposi's sarcoma-associated herpesvirus DNA sequences in prostate tissue and human semen. N Engl J Med 1996;334:1168-72.
51. Miller G, Rigsby MO, Heston L, Grogan E, Sun R, Metroka C, et al. Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med 1996;334:1292-7.
52. Gao S-J, Kingsley L, Hoover DR, Spira TJ, Rinalso CR, Saah A, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 1996;335:233-41.
53. Nelson KE, Celentano DD, Eiumtrakol S, Hoover DR, Beyrer C, Suprasert S, et al. Changes in sexual behavior and decline in HIV infection among young men in Thailand. N Engl J Med 1996;335:297-303.
54. Robinson NJ, Silarug N, Surasiengsunk S, Auvert B, Hanenberg R. Two million HIV infections prevented in Thailand: estimate of the impact of increased condom use. XI International Conference on AIDS, Vancouver, 1996. (Abstract MoC904.)
55. Grosskurth H, Mosha F, Todd J, Mwifarubi E, Klokke A Sendoro, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomized controlled trial. Lancet 1995;346:530-6.
56. Wawer MJ, Sewankambo NK, Gray RH, Serwadda D, Paxton L, Quinn TC, et al. Community-based trial of mass STD treatment for HIV control, Rakai, Uganda: preliminary data on STD declines. XI International Conference on AIDS, Vancouver, 1996. (Abstract MoC443.)